



HIV & HEPATITIS NORDIC CONFERENCE

HOTEL HILTON STOCKHOLM SLUSSEN

26-28
SEPTEMBER
2018

Wednesday September 26

Coffe and sandwich will be served from 08.30

09.00-10.00 **Registration**

Opening session

10.15-10.20 Welcome (Nina Weis, Denmark)

10.20-10.50 **Opening Plenary 1**

Progress towards reaching the 90-90-90 HIV target in Europe and beyond
(Anastasia Pharris, ECDC, Sweden)

10.50-11.00 Discussion

Abstract Session I

11.00-11.15 Oral 1 (10 min + 5 min discussion)

11.15-11.30 Oral 2

11.30-11.45 Oral 3

11.45-12.00 Oral 4

12.00-13.00 **Lunch**

Plenary Session I

13.00-13.30 Plenary 2. Mortality and morbidity among children and adolescents with perinatal HIV infection (Ruth Goodall, UK)

13.30-13.40 Discussion

13.40-14.10 Plenary 3. HIV infected women and breastfeeding (Ellen Moseholm Larsen, Denmark)

14.10-14.20 Discussion

14.20-14.35 Short break

14.35-15.50 **BHIVA and HIV Nordic joint session – Aspects on HIV prevention in high-risk-populations**

Chemsex (Ann Sullivan, UK)

PrEP, implementation in Norway (Frank Olav Pettersen, Norway)

Declining HIV prevalence among MSM in London (Ann Sullivan, UK)

Discussion

15.50-16.30 Coffee and exhibition/posters

16.30-17.30 Satellite Symposium I

17.30-17.45 Short break

17.45-18.45 Satellite Symposium II

18.45- Poster Exhibition with cheese and snacks



HIV & HEPATITIS NORDIC CONFERENCE

HOTEL HILTON STOCKHOLM SLUSSEN

26-28
SEPTEMBER
2018

Thursday September 27

- 08.00-09.00 Satellite Symposium III
- 09.00-09.10 Short break
- Plenary Session III – Inflammation and reservoirs**
- 09.10-09.40 Plenary 6. Tissue resident T-cells and immunity during acute and chronic HIV-infection (Mike Betts, USA)
- 09.40-09.50 Discussion
- 09.50-10.20 Plenary 7. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation (Piotr Nowak, Sweden)
- 10.20-10.30 Discussion
- 10.30-11.00 Coffee and exhibition/posters
- 11.00-11.30 Plenary 8. Is it possible to enhance immune function in HIV-infected persons on ART with immune failure? (Michael Lederman, USA)
- 11.30-11.40 Discussion
- Plenary Session IV – Living with HIV**
- 11.40-12.10 Plenary 9. Life expectancy and long-term outlook in PLHIV (Caroline Sabin, UK)
- 12.10-12.20 Discussion
- 12.20-12.50 Plenary 10. Recent achievements in Next-Generation Sequencing (NGS) of HIV and possible clinical implications (Roger Paredes, Spain)
- 12.50-13.00 Discussion
- 13.00-14.00 Lunch
- Plenary Session V – Last year's most important achievements in the HIV research field**
- 14.00-14.30 Plenary 11. Top 5 in basic HIV research 2016-2017 (Jan Albert, Sweden)
- 14.30-14.40 Discussion
- 14.40-15.10 Plenary 12. Top 5 in clinical HIV research 2017-2018 (Anne-Mette Kjær Lebech, Denmark)
- 15.10-15.20 Discussion
- 15.20-15.30 Plenary 13. The history of HIV in Finland (Matti Ristola, Finland)
- 15.30-15.45 HIV & Hepatitis Nordic Conference 2018 Abstract Award
Matti Ristola, Finland)
- 15.45-16.15 Coffee and exhibition/posters
- 16.15-17.15 Satellite Symposium IV
- 17.15-17.30 Short break
- 17.30-18.30 Satellite Symposium V
Conference dinner



HIV & HEPATITIS NORDIC CONFERENCE

HOTEL HILTON STOCKHOLM SLUSSEN

26-28
SEPTEMBER

2018

Friday September 28

- 08.00-09.00 Satellite Symposium VI
Plenary Session VI – Last year's most important achievements in the hepatitis field
- 09.10-09.40 Plenary 14. Top 5 in hepatitis research 2017/18 (Martti Färkkilä, Finland)
- 09.40-09.50 Discussion
Abstract Session II
- 09.50-10.05 Oral 5 (10 + 5 min discussion)
- 10.05-10.20 Oral 6
- 10.20-11.00 Coffee and exhibition/posters
Plenary Session VII
- 11.00-11.30 Plenary 15. Update on hepatitis E (Heléne Norder, Sweden)
- 11.30-11.40 Discussion
- 11.40-12.10 Plenary 16. Can HCC surveillance be stopped?/ Post SVR surveillance (Sofie Hallager, Denmark)
- 12.10-12.20 Discussion
- 12.20-13.20 Lunch
Plenary Session VIII – Hepatitis C
- 13.20-13.50 Plenary 17. HCV treatment in needle exchange programs (Marianne Alanko, Sweden)
- 13.50-14.00 Discussion
- 14.00-14.30 Plenary 18. HCV treatment in the prison systems (Soo Aleman, Sweden)
- 14.30-14.40 Discussion
- 14.40-15.10 Plenary 19. Global Perspectives on HCV Eradication (TBD)
- 15.10-15.20 Discussion
- 15.20-15.30 Concluding remarks